Simufilam Reverses Aberrant Receptor Interactions of Filamin A in Alzheimer’s Disease

Simufilam is a novel oral drug candidate in Phase 3 clinical trials for Alzheimer’s disease (AD) dementia. This small molecule binds an altered form of filamin A (FLNA) that occurs in AD. This drug action disrupts FLNA’s aberrant linkage to the α7 nicotinic acetylcholine receptor (α7nAChR), thereby...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hoau-Yan, Cecon, Erika, Dam, Julie, Pei, Zhe, Jockers, Ralf, Burns, Lindsay H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531384/
https://www.ncbi.nlm.nih.gov/pubmed/37762230
http://dx.doi.org/10.3390/ijms241813927

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531384/
https://www.ncbi.nlm.nih.gov/pubmed/37762230
http://dx.doi.org/10.3390/ijms241813927

Ejemplares similares